Diagnosis of osteoporosis based on dual-energy X-ray absorptiometry (DXA) criteria (T-score ≤ -2.5 at the lumbar spine, total hip, or femoral neck) or presence of a prior fragility fracture
Planned initiation of antiresorptive therapy (denosumab or bisphosphonate) as part of routine clinical care
Ability to undergo DXA measurements at baseline and during follow-up
Ability and willingness to provide written informed consent
You may not be if
Diagnosis of diabetes mellitus (type 1 or type 2)
Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m²
Active malignancy or history of malignancy within the past 5 years
Secondary causes of osteoporosis (including hyperparathyroidism, hyperthyroidism, Cushing's syndrome, malabsorption syndromes, or chronic liver disease)
Use of medications known to significantly affect bone metabolism other than antiresorptive therapy (e.g., long-term systemic glucocorticoids, anabolic osteoporosis agents)
Prior treatment with denosumab or bisphosphonates within the last 12 months
Inflammatory rheumatic diseases or chronic inflammatory conditions that may affect bone metabolism
Pregnancy or breastfeeding
Inability to comply with study procedures or follow-up visits